Sei Investments Co. Buys 49,198 Shares of Agios Pharmaceuticals, Inc. $AGIO

Sei Investments Co. grew its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 342.8% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 63,550 shares of the biopharmaceutical company’s stock after purchasing an additional 49,198 shares during the quarter. Sei Investments Co.’s holdings in Agios Pharmaceuticals were worth $2,150,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Wellington Management Group LLP grew its stake in shares of Agios Pharmaceuticals by 485.5% in the third quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after buying an additional 2,049,287 shares in the last quarter. MPM Bioimpact LLC bought a new stake in Agios Pharmaceuticals during the fourth quarter worth $35,478,000. State Street Corp raised its position in Agios Pharmaceuticals by 37.4% during the fourth quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock worth $84,604,000 after acquiring an additional 845,433 shares in the last quarter. TCG Crossover Management LLC lifted its stake in Agios Pharmaceuticals by 105.2% in the third quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock valued at $57,402,000 after acquiring an additional 733,038 shares during the last quarter. Finally, Capital International Investors acquired a new stake in Agios Pharmaceuticals in the fourth quarter valued at $19,159,000.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total value of $914,400.00. Following the completion of the sale, the insider owned 54,645 shares in the company, valued at $1,665,579.60. The trade was a 35.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 5.40% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on AGIO shares. Royal Bank Of Canada boosted their price objective on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research note on Tuesday, July 7th. HC Wainwright raised their target price on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. JPMorgan Chase & Co. lifted their price target on Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a report on Friday. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, June 24th. Finally, Citigroup boosted their price objective on Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Five investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Agios Pharmaceuticals has an average rating of “Hold” and a consensus price target of $41.25.

Agios Pharmaceuticals Price Performance

AGIO stock opened at $32.27 on Monday. The stock has a market capitalization of $1.93 billion, a price-to-earnings ratio of -4.60 and a beta of 0.58. The business’s fifty day moving average price is $34.75 and its two-hundred day moving average price is $31.04. Agios Pharmaceuticals, Inc. has a fifty-two week low of $22.24 and a fifty-two week high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. The business had revenue of $44.75 million during the quarter, compared to the consensus estimate of $26.39 million. Research analysts expect that Agios Pharmaceuticals, Inc. will post -6.12 EPS for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.